1195-06-8

Basic information

• Product Name: 4-ethylbenzene-1,3-diamine
• Synonyms: 4-ethylbenzene-1,3-diamine;4-Ethyl-1,3-benzenediamine
• CAS NO: 1195-06-8
• Molecular Formula: C₈H₁₂N₂
• Molecular Weight: 136.19428
• EINECS: 214-790-1
• Mol File: 1195-06-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 292.1°Cat760mmHg
• Flash Point: 154.2°C
• Appearance: /
• Density: 1.073g/cm³
• Vapor Pressure: 0.00187mmHg at 25°C
• Refractive Index: 1.615
• CAS DataBase Reference: 4-ethylbenzene-1,3-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ethylbenzene-1,3-diamine(1195-06-8)
• EPA Substance Registry System: 4-ethylbenzene-1,3-diamine(1195-06-8)

Safety Data

• Hazardous Substances Data: 1195-06-8(Hazardous Substances Data)

Usage

General Description

4-ethylbenzene-1,3-diamine, also known as 1,3-diethylbenzene-1,3-diamine, is an organic compound with the molecular formula C10H16N2. It is a type of aromatic amine, which is commonly used in the production of various polymers and coatings. This chemical is typically used as a building block for the synthesis of dyes and pigments, as well as in the manufacturing of pharmaceuticals and agricultural chemicals. It has a role as an allergen and is known to be a skin irritant, so proper handling and safety precautions are important when working with this substance.

InChI:InChI=1/C8H12N2/c1-2-6-3-4-7(9)5-8(6)10/h3-5H,2,9-10H2,1H3

Upstream product

• 74-85-1 ethene 
• 108-45-2 m-phenylenediamine 
• 100-41-4 ethylbenzene 
• 1204-29-1 1-ethyl-2,4-dinitrobenzene 

Downstream Products

• 873050-25-0 N-(3-amino-4-ethylphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 
• 87739-64-8 1-(3-Amino-4-ethyl-phenyl)-6,6-dimethyl-1,6-dihydro-[1,3,5]triazine-2,4-diamine; hydrochloride 
• 21897-43-8 4-ethyl-m-phenylene diisocyanate 

Relevant articles and documents

Catalytic hydrogenation of 2,4-dinitroethylbenzene to 2,4- diaminoethylbenzene over Ni/HY catalysts: The solvent effect

Catalytic hydrogenation of 2,4-dinitroethylbenzene over Ni/HY catalysts in different solvents was studied, which demonstrated that the reaction exhibits the best performance in protic solvents. The reason is hypothesized to be the strong hydrogen-bond interaction between the protic solvents with the reactant, intermediates and product due to their excellent hydrogen-bond donating capability, which favors the desorption of the adsorbed intermediates and product from the catalysts and helps to polarize the NO bonds of the reactant and intermediates. Subsequently, the hydrogenation in the mixed solvents of water and ethanol was investigated, which showed that the reaction can be significantly accelerated by adding water into ethanol and the optimum volume percentage of water is verified to be 40%.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.